CFTR Limits F-actin Formation and Promotes Morphological Alignment with Flow in Human Lung Microvascular Endothelial Cells
Overview
Authors
Affiliations
Micro- and macrovascular endothelial dysfunction in response to shear stress has been observed in cystic fibrosis (CF), and has been associated with inflammation and oxidative stress. We tested the hypothesis that the cystic fibrosis transmembrane conductance regulator (CFTR) regulates endothelial actin cytoskeleton dynamics and cellular alignment in response to flow. Human lung microvascular endothelial cells (HLMVEC) were cultured with either the CFTR inhibitor GlyH-101 (20 µM) or CFTRinh-172 (20 µM), tumor necrosis factor (TNF)-α (10 ng/ml) or a vehicle control (0.1% dimethyl sulfoxide) during 24 and 48 h of exposure to shear stress (11.1 dynes/cm ) or under static control conditions. Cellular morphology and filamentous actin (F-actin) were assessed using immunocytochemistry. [Nitrite] and endothelin-1 ([ET-1]) were determined in cell culture supernatant by ozone-based chemiluminescence and ELISA, respectively. Treatment of HLMVECs with both CFTR inhibitors prevented alignment of HLMVEC in the direction of flow after 24 and 48 h of shear stress, compared to vehicle control (both p < 0.05). Treatment with TNF-α significantly increased total F-actin after 24 h versus control (p < 0.05), an effect that was independent of shear stress. GlyH-101 significantly increased F-actin after 24 h of shear stress versus control (p < 0.05), with a significant (p < 0.05) reduction in cortical F-actin under both static and flow conditions. Shear stress decreased [ET-1] after 24 h (p < 0.05) and increased [nitrite] after 48 h (p < 0.05), but neither [nitrite] nor [ET-1] was affected by GlyH-101 (p > 0.05). CFTR appears to limit cytosolic actin polymerization, while maintaining a cortical rim actin distribution that is important for maintaining barrier integrity and promoting alignment with flow, without effects on endothelial nitrite or ET-1 production.
CFTR dictates monocyte adhesion by facilitating integrin clustering but not activation.
Younis D, Marosvari M, Liu W, Pulikkot S, Cao Z, Zhou B Proc Natl Acad Sci U S A. 2025; 122(3):e2412717122.
PMID: 39813254 PMC: 11760921. DOI: 10.1073/pnas.2412717122.
Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis.
Causer A, Shute J, Cummings M, Shepherd A, Wallbanks S, Pulsford R Pediatr Pulmonol. 2022; 57(11):2652-2658.
PMID: 35851858 PMC: 9795914. DOI: 10.1002/ppul.26078.
Causer A, Khalaf M, Klein Rot E, Brand K, Smith J, Bailey S Physiol Rep. 2021; 9(23):e15128.
PMID: 34851051 PMC: 8634629. DOI: 10.14814/phy2.15128.